Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial.
Li J, Shi LW, Li K, Huang LR, Li JB, Dong YL, Li W, Ji M, Yang Q, Zhou LY, Yuan L, Yan XM, Chen JJ, Jiang ZW, Qi YY, Li RC, Li YP, Xia JL, Yu BW, Mo ZJ, Li CG.
Li J, et al. Among authors: li rc.
Vaccine. 2023 Oct 26;41(48):7212-9. doi: 10.1016/j.vaccine.2023.10.041. Online ahead of print.
Vaccine. 2023.
PMID: 39492306
Free PMC article.